WO2001038498A3 - A new genotype of hepatitis b virus - Google Patents

A new genotype of hepatitis b virus Download PDF

Info

Publication number
WO2001038498A3
WO2001038498A3 PCT/US2000/032108 US0032108W WO0138498A3 WO 2001038498 A3 WO2001038498 A3 WO 2001038498A3 US 0032108 W US0032108 W US 0032108W WO 0138498 A3 WO0138498 A3 WO 0138498A3
Authority
WO
WIPO (PCT)
Prior art keywords
virus
hepatitis
sample
genotype
nucleic acid
Prior art date
Application number
PCT/US2000/032108
Other languages
French (fr)
Other versions
WO2001038498A2 (en
Inventor
Lieven Stuyver
Raymond Schinazi
Gendt Sija De
Geyt Caroline Van
Fabien Zoulim
Michael Fried
Rudi Rossau
Original Assignee
Pharmasset Ltd
Innogenetics Nv
Lieven Stuyver
Raymond Schinazi
Gendt Sija De
Geyt Caroline Van
Fabien Zoulim
Michael Fried
Rudi Rossau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmasset Ltd, Innogenetics Nv, Lieven Stuyver, Raymond Schinazi, Gendt Sija De, Geyt Caroline Van, Fabien Zoulim, Michael Fried, Rudi Rossau filed Critical Pharmasset Ltd
Priority to EP00980687A priority Critical patent/EP1238061A2/en
Publication of WO2001038498A2 publication Critical patent/WO2001038498A2/en
Publication of WO2001038498A3 publication Critical patent/WO2001038498A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides a purified hepatitis B virus, genotype G. Also provided are methods of detecting hepatitis B virus, genotype G in a sample, comprising: (a) contacting the sample with an antibody of this invention under conditions whereby an antigen/antibody complex can form; and (b) detecting the presence of the antigen/antibody complex, whereby the detection of the antigen/antibody complex indicates the presence of hepatitis B virus, genotype G in a sample. Further provided is a method of detecting hepatitis B virus, genotype G in a sample, comprising: (a) contacting the sample with a nucleic acid of this invention under conditions whereby the nucleic acid can hybridize with a nucleic acid sequence in the sample; and (b) detecting the presence of nucleic acid hybridization complexes, whereby the detection of the hybridization complexes indicates the presence of hepatitis B virus, genotype G in the sample. Additional methods related to HBV, genotype G are also provided.
PCT/US2000/032108 1999-11-24 2000-11-21 A new genotype of hepatitis b virus WO2001038498A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP00980687A EP1238061A2 (en) 1999-11-24 2000-11-21 A new genotype of hepatitis b virus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16720699P 1999-11-24 1999-11-24
US60/167,206 1999-11-24

Publications (2)

Publication Number Publication Date
WO2001038498A2 WO2001038498A2 (en) 2001-05-31
WO2001038498A3 true WO2001038498A3 (en) 2002-01-24

Family

ID=22606391

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/032108 WO2001038498A2 (en) 1999-11-24 2000-11-21 A new genotype of hepatitis b virus

Country Status (2)

Country Link
EP (1) EP1238061A2 (en)
WO (1) WO2001038498A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034841B2 (en) 2011-04-21 2015-05-19 Isis Pharmaceuticals, Inc. Modulation of hepatitis B virus (HBV) expression

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2486420C (en) 2002-06-14 2014-04-15 Gen-Probe Incorporated Compositions and methods for detecting hepatitis b virus
JP2008525029A (en) * 2004-12-22 2008-07-17 ニュークレオニクス・インコーポレイテッド HBV and HCV conserved sequences useful for gene silencing
JOP20200092A1 (en) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
KR20210043647A (en) 2018-08-13 2021-04-21 알닐람 파마슈티칼스 인코포레이티드 Hepatitis B virus (HBV) dsRNA preparation composition and method of use thereof
WO2021060450A1 (en) * 2019-09-27 2021-04-01 富士レビオ株式会社 Immunoassay for hepatitis b virus core-related antigen and kit therefor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02163089A (en) * 1988-12-15 1990-06-22 Dai Ichi Seiyaku Co Ltd Hbv-dna sequence and trans-genic animal

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02163089A (en) * 1988-12-15 1990-06-22 Dai Ichi Seiyaku Co Ltd Hbv-dna sequence and trans-genic animal

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199031, Derwent World Patents Index; Class B04, AN 1990-235346, XP002166266 *
STUYVER LIEVEN ET AL: "A new genotype of hepatitis B virus: Complete genome and phylogenetic relatedness.", JOURNAL OF GENERAL VIROLOGY, vol. 81, no. 1, January 2000 (2000-01-01), pages 67 - 74, XP000993120, ISSN: 0022-1317 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034841B2 (en) 2011-04-21 2015-05-19 Isis Pharmaceuticals, Inc. Modulation of hepatitis B virus (HBV) expression
US9127278B2 (en) 2011-04-21 2015-09-08 Isis Pharmaceuticals, Inc. Modulation of hepatitis B virus (HBV) expression

Also Published As

Publication number Publication date
WO2001038498A2 (en) 2001-05-31
EP1238061A2 (en) 2002-09-11

Similar Documents

Publication Publication Date Title
EP0875584A3 (en) Nucleic acid assays
WO2001096608A8 (en) Detection of nucleic acids by type-specific hybrid capture method
CA2191182A1 (en) Oligonucleotide primers for amplifying hcv nucleic acid
MX2013008116A (en) Quantifying frustration via a user interface.
JPH0398600A (en) Detection of influenza virus a by polymerase chain reaction after reverse transcription of genetic region of virus blood corpuscle hemagglutinin
Weber et al. Improved detection of hepatitis B virus surface antigen by a new rapid automated assay
CA2588581A1 (en) Detection of nucleic acids from multiple types of human papillomaviruses
JP2690738B2 (en) Nucleic acid detection method and device
EP0618924A1 (en) Hbv amplifier probes for use in solution phase sandwich hybridization assays
CA2139070A1 (en) Method for enhancing detection ability of nucleic acid assays employing polymerase chain reaction
WO2003002749A3 (en) Methods for the simultaneous detection of hcv antigens and hcv antibodies
WO2003033735A3 (en) Test strip assay system and method for the detection of specific nucleic acid sequences
EP1174523A3 (en) Method for detecting an HBV-derived nucleic acid target sequence
WO2004020654A3 (en) Solid phase based nucleic acid assays combining high affinity and high specificity
WO2001038498A3 (en) A new genotype of hepatitis b virus
WO2003038121A3 (en) Method for the detection of cytosine methylation in immobilised dna samples
WO2000050564A3 (en) Method for extracting dna from dried specimens
WO2002004484A3 (en) Hcv mosaic antigen composition
EP1500710A4 (en) Method of detecting target nucleic acid
WO1991000868A1 (en) Immobilised polynucleotides
CN109884304B (en) CHA amplification reaction system of HCV core protein and ultra-sensitive visual detection method
Japanese Red Cross NAT Screening Research Group Nationwide nucleic acid amplification testing of hepatitis B virus, hepatitis C virus and human immunodeficiency virus type 1 for blood transfusion and follow-up study of nucleic acid amplification positive donors
ATE305522T1 (en) DETECTION OF HUMAN PAPILLOMA VIRUSES
EP0922771A3 (en) Method for the detection of large concentrations of a virus in blood plasma and/ or blood serum using the polymerase chain reaction
WO2000066774A3 (en) Improved assay and reagents therefor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

WWE Wipo information: entry into national phase

Ref document number: 2000980687

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000980687

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000980687

Country of ref document: EP